Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/19 → 3/4/23 |
Funding
- AbbVie Inc. (Protocol M16-000)
Protocol M16-000: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006
Project: Research project